

## SPECTROPHOTOMETRIC DETERMINATION OF DRUGS BY USING CHLORAMINE-T AND METHYL ORANGE

M. Sasikala, K. Sayanna and G.Venkateshwarlu\*

Department of Chemistry, University College of Science, Osmania University, Hyderabad-500007, India.

Article Received on  
21 Nov 2014,

Revised on 16 Dec 2014,  
Accepted on 10 Jan 2015

\*Correspondence for  
Author

G.Venkateshwarlu

Department of  
Chemistry, University  
college of science,  
Osmania university,  
Hyderabad-500007, India

### ABSTRACT

Simple and sensitive validated spectrophotometric methods has been developed for the assay of five drugs *viz.*, Gemifloxacin (GEM), Ondansetron (OND), Alfuzocin (ALF), Duloxetine (DUL) and Torsemide (TOR) in pure and pharmaceutical formulations. The proposed method was based on the oxidation of drug by Chloramine-T (excess) and subsequent determination of unreacted Chloramine-T using methyl orange as analytical tool which absorbs at 510 nm. Beer's law is obeyed in the concentration of 2-14 , 4-28 , 3-24 , 3-21 and 1.5-8.5  $\mu\text{g mL}^{-1}$  for GEM, OND, ALF, DUL and TOR respectively. Different variables affecting the reaction were studied and optimized. The proposed methods were applied successfully to the determination

of the examined drugs in pure and pharmaceutical dosage forms with good accuracy and precision.

**KEYWORDS:** spectrophotometry, Chloramine-T, methyl orange and formulations.

### INTRODUCTION

1. **Gemifloxacin** (GEM) "Fig.1a" is chemically known as 7-[(4Z)-3-(Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1, 8-naphthyridine-3-carboxylic acid. It is used to treat a variety of bacterial infections. This medication belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections.<sup>[1]</sup> It will not work for virus infections. Because of its physiological significance the drug has been quantitatively analyzed by different methods. A few analytical methods like HPLC<sup>[2-5]</sup>, Spectrophotometry<sup>[6,7]</sup>, Spectrofluorimetry

[8, 9], LC-MS<sup>[10]</sup>, and Chemiluminisence method<sup>[11]</sup> developed for the estimation of GEM are mention worthy.

**2. Ondansetron (OND)** “Fig.1b” is chemically known as (RS)-9-methyl-3-[(2-methyl-1H-imidazol-1-yl) methyl]-2,3-dihydro-1H-carbazol-4(9H)-one. It is a serotonin 5-HT<sub>3</sub> receptor antagonist used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. It has little effect on vomiting caused by motion sickness,<sup>[12]</sup> and does not have any effect on dopamine receptors or muscarinic receptors. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. . An extensive literature survey revealed that spectrophotometry<sup>[13-16]</sup>, HPLC<sup>[17-21]</sup> and LC<sup>[22]</sup> have been applied for the analysis of OND in bulk and in formulations.

**3. Alfuzocin (ALF)** “Fig.1c” is chemically known as N-[3-[(4-amino-6, 7-dimethoxyquinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide. It is a  $\alpha$ 1 receptor antagonist used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.<sup>[23]</sup> Analytical methods available for the determination of ALF include spectrophotometry<sup>[24-28]</sup>, HPLC<sup>[29-30]</sup>, LC<sup>[31]</sup>, Conductometry<sup>[32]</sup>, Colorimetry.<sup>[33]</sup>

**4. Duloxetine (DUL)** “Fig.1d” is chemically known as (+)-(S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl) propan-1-amine. The main uses of duloxetine are in major depressive disorder, general anxiety disorder, urinary incontinence, painful peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain associated with osteoarthritis and chronic lower back pain.<sup>[34]</sup> Literature review reveals that a few methods have been published for analysis of DUL in the bulk form and in pharmaceutical preparations. Methods available include HPLC<sup>[35-37]</sup>, UPLC<sup>[38]</sup> and Spectrophotometry.<sup>[39, 40]</sup>

**5. Torsemide (TOR)** “Fig.1e” is chemically known as N-[(isopropyl amino) carbonyl]-4-[(3-methylphenyl) amino]pyridine-3-sulfonamide. It is mainly used in the management of edema associated with congestive heart failure.<sup>[41]</sup> It is also used at low doses for the management of hypertension. . Several techniques have been reported in the literature for the determination of TOR in pharmaceuticals and in biological samples include HPLC<sup>[42-46]</sup>, Spectrophotometry<sup>[47-52]</sup> in pharmaceuticals and in biological samples.

## MATERIALS AND METHODS






**Instrumentation :** Spectral and absorbance measurements were made on a Elico 210 double beam spectrophotometer , Systronics 117 spectrophotometer and also on ELICO 159 UV-VIS single beam spectrophotometers using quartz cells of 10 mm path length. A Dhona 200 single pan electrical balance is used for weighing the samples.

**Reagents:** Gemifloxacin, Ondansetron, Alfuzocin, Duloxetine and Torsemide drug samples were procured from Hetero drugs pvt limited, Hyderabad as gift samples. The reagents Chloramine-T, methyl orange (AR grade) and HCl supplied by SD Fine chemicals Ltd. Mumbai, are used without any further purification.

**Drug solutions:** A stock solution of each drug is prepared in doubly distilled water by dissolving 25mg of drug in 25ml of water and the stock is diluted to the required concentrations. A 0.01 M of Chloramine-T and  $5 \times 10^{-4}$  M Methyl orange are prepared in distilled water and 0.5M HCl is prepared from stock. The concentrations of the Chloramine-T and Methyl Orange are set such that 1ml of Chloramine-T in the presence of 1ml of acid exactly neutralize 1ml of Methyl Orange and shows zero absorbance.


## RESULT AND DISCUSSION

**Procedure for Calibration:** Different aliquots of drug solution (1-7 ml) were taken into a 10ml standard flask to which 1ml of acid and 1ml of Chloramine-T were added. The contents were occasionally shaken for 15 minutes and finally 1ml of methyl orange is added, the volume is made up to mark using distilled water. Absorbance was measured at 510nm against the blank prepared similarly. The same procedure of analysis is followed either for assay of pure drug or for dosage form. The calibration graphs "Fig. 2" are linear over the concentration ranges are within the permissible range. The optical characteristics and statistical data for the regression equation of the proposed methods are presented in [Table 1.] Six replicate experiments performed and the relative response i.e., absorbance / concentration ( $\mu\text{g mL}^{-1}$ ) was calculated. The points falling between 95% and 105% of average only are considered for the construction of calibration. The standard deviation of six residual intercepts of the plots is used for calculating LOD and LOQ.

**a. Gemifloxacin****b. Ondansetron****c. Alfuzocin****d. Duloxetine****e. Torsemide****Fig.1. Structures Of The Drugs**

### Procedure for Assay of Pure Drugs

To test the accuracy and precision of the methods developed, pure sample solutions containing drug in Beer's law limit were chosen. For this study 2.5, 3.0, 3.5 and 4.0  $\mu\text{g mL}^{-1}$  of GEM ; 4.0, 10.0, 12.0 and 16.0  $\mu\text{g mL}^{-1}$  of OND; 3.0, 5.5, 9.0 and 12.5  $\mu\text{g mL}^{-1}$  of ALF; 3.0, 3.5, 4.0 and 4.5  $\mu\text{g mL}^{-1}$  of DUL; 2.0, 3.0, 4.0 and 5.0  $\mu\text{g mL}^{-1}$  of TOR have been taken and the recovery experiments were performed. The recoveries and their relative standard deviations are tabulated in [Table. 2]



**Fig.2 Calibration curves for the determination of drugs.**

### Method Validation

Each method developed for quantification of drugs has been validated in terms of precision, accuracy, limit of detection, limit of quantification, linearity, selectivity and ruggedness. The Beer's law limits, Slope, Intercept, Correlation coefficient, Sandell's sensitivity and Regression equation for each drug are tabulated in [Table 1]. To assess the precision each experiment was repeated at least 5 times and accuracy is estimated in terms of % recovery and % RSD. Excellent % recovery and RSD being less than 2 for each drug demonstrates accuracy and precision of the methods. Further t-test and F- test values have also been calculated using a standard reference method for each drug. The t-test and F-test values are less than their permissible range indicating high accuracy and precision of the methods [Table 2].

### Analysis of Pharmaceuticals

#### Gemifloxacin

Twenty capsules of EG 1 were weighed accurately and crushed to fine powder. Quantity of tablet powder equivalent to 50mg of analyte was weighed and transferred to 100ml volumetric flask and dissolved in 40 ml of distilled water by using 0.2M HCl. This solution was then filtered through Whatmann filter paper No.41. The volume was made up to the mark of 100ml volumetric flask with distilled water.

**Ondansetron**

Twenty tablets of Ondem were finely grinded and mixed. An accurately weighed 50 mg of OND was taken into a 100 ml volumetric flask, sonicated and remaining volume is made up with distilled water.

**Alfuzosin**

Ten tablets of Alfoo were weighed accurately and powdered. The powder equivalent to 50 mg was transferred into a 100 ml volumetric flask, containing a mixture of distilled water (10.0 ml) and HCl (2.0 ml). The flask was shaken for 5 mins and the solution was filtered using whatmann No.41 filter paper and further diluted with water to obtain working standard solution.

**Duloxetine**

Twenty tablets of Diligo were weighed and ground into a fine powder. An amount of tablet powder equivalent to 50 mg of DUL was weighed and transferred into 100 ml beaker containing 50 ml of 0.2 M HCl. After shaking the contents for 20 mins, filtered through Whatmann No. 41 filter paper into a clean 100 ml volumetric flask and the volume was brought up to the mark with the distilled water.

**Torseamide**

Twenty tablets of Dytor were finely grounded and mixed. An accurately weighed 50 mg of TOR was transferred into a 100 ml volumetric flask and dissolved in HCl. Then the solution was filtered using Whatmann No.41 filter paper and further diluted with distilled water and made volume up to the mark.

To test the applicability of the method developed, pharmaceutical tablet solutions containing drug in the Beer's Law limit were chosen. For this study 2.5, 3.0, 3.5 and 4.0  $\mu\text{g mL}^{-1}$  of GEM; 4.0, 10.0, 12.0 and 16.0  $\mu\text{g mL}^{-1}$  of OND; 3.0, 5.5, 9.0 and 12.5  $\mu\text{g mL}^{-1}$  of ALF; 3.0, 3.5, 4.0 and 4.5  $\mu\text{g mL}^{-1}$  of DUL and 2.0, 3.0, 4.0 and 5.0  $\mu\text{g mL}^{-1}$  of TOR; were chosen [Table.3]

**Effect of acid concentration:** HCl was the medium of choice for estimation of drugs Chloramine-T and Methyl Orange. The absorbance of Methyl orange was not affected in 0.125-1.25 M HCl concentration. A 0.5 M HCl concentration was found optimum for the estimation of drugs in a reasonable time of 5-10 mins and hence the same concentration was employed for the determination of drugs by using Chloramine-T and Methyl Orange.

**Table 1: Analytical and regression parameters of spectrophotometric study**

| Parameter  | GEM                  | OND                   | ALF                   | DUL                  | TOR                   |
|--|----------------------|-----------------------|-----------------------|----------------------|-----------------------|
| $\lambda_{\max}$ , nm                                  | 510                  | 510                   | 510                   | 510                  | 510                   |
| Beer's law limits $\mu\text{g mL}^{-1}$                | 2-14                 | 4-28                  | 3-24                  | 3-21                 | 1.5-8.5               |
| Molar absorptivity, $\text{L mol}^{-1} \text{cm}^{-1}$ | $5.5 \times 10^{-3}$ | $1.17 \times 10^{-3}$ | $1.77 \times 10^{-3}$ | $1.0 \times 10^{-3}$ | $2.51 \times 10^{-3}$ |
| Sandell sensitivity* $\mu\text{g cm}^{-2}$             | 0.0188               | 0.034483              | 0.0303                | 0.03333              | 0.013889              |
| Limit of detection $\mu\text{g mL}^{-1}$               | 2.4561               | 2.035593              | 0.258844              | 0.004803             | 0.01244               |
| Limit of quantification $\mu\text{g mL}^{-1}$          | 7.442816             | 6.168463              | 0.784374              | 0.014555             | 0.037697              |
| Regression equation,<br>$Y^{**}=a+bX$                  | 0.086<br>+0.053X     | 0.053<br>+0.029X      | 0.050<br>+0.033X      | 0.03X                | -0.003<br>+0.072X     |
| Slope, (b)   | 0.053                | 0.029                 | 0.033                 | 0.03                 | 0.072                 |
| Intercept, (a)   | 0.086                | 0.053                 | 0.050                 | 0.00                 | -0.003                |
| Correlation coefficient, (r)                           | 0.998                | 0.993                 | 0.994                 | 1.00                 | 0.999                 |
| Regression equation,<br>$Y^{**}=a+bX$                  | 0.086<br>+0.053X     | 0.053<br>+0.029X      | 0.050<br>+0.033X      | 0.03X                | -0.003<br>+0.072X     |

\*Limit of determination as the weight in  $\mu\text{g}$  per mL of solution, which corresponds to an absorbance of  $A = 0.001$  measured in a cuvette of cross-sectional area  $1 \text{ cm}^2$  and path length of  $1 \text{ cm}$ .  $Y^{**} = a+bX$ , where Y is the absorbance and X=concentration of drug ( $\mu\text{g mL}^{-1}$ )

**Table 2: Determination of accuracy and precision of the methods on pure drug Samples.**

| Drug | Amount Taken ( $\mu\text{g mL}^{-1}$ ) | Amount Found ( $\mu\text{g mL}^{-1}$ ) | (%) ER | %Recovery | %RSD  | Proposed method Mean $\pm$ SD |
|------|--|--|--------|-----------|-------|-------------------------------|
| GEM  | 2.5                                    | 2.48                                   | 0.8    | 99.2      | 1.192 | 99.89 $\pm$ 1.201             |
|      | 3.0                                    | 3.05                                   | 1.6    | 101.67    |       |                               |
|      | 3.5                                    | 3.48                                   | 0.57   | 99.43     |       |                               |
|      | 4.0                                    | 3.97                                   | 0.75   | 99.25     |       |                               |
| OND  | 4.0                                    | 3.98                                   | 0.5    | 99.5      | 0.164 | 99.69 $\pm$ 0.162             |
|      | 10.0                                   | 9.96                                   | 0.4    | 99.6      |       |                               |
|      | 12.0                                   | 11.98                                  | 0.167  | 99.83     |       |                               |
|      | 16.0                                   | 15.97                                  | 0.19   | 99.81     |       |                               |
| ALF  | 3.0                                    | 2.98                                   | 0.67   | 99.33     | 0.386 | 99.87 $\pm$ 0.390             |
|      | 5.5                                    | 5.51                                   | 0.18   | 100.18    |       |                               |
|      | 9.0                                    | 9.01                                   | 0.11   | 100.11    |       |                               |
|      | 12.5                                   | 12.48                                  | 0.16   | 99.84     |       |                               |
| DUL  | 3.0                                    | 2.95                                   | 1.67   | 98.33     | 0.655 | 99.12 $\pm$ 0.649             |
|      | 3.5                                    | 3.46                                   | 1.14   | 98.86     |       |                               |
|      | 4.0                                    | 3.98                                   | 0.5    | 99.5      |       |                               |
|      | 4.5                                    | 4.49                                   | 0.22   | 99.78     |       |                               |
| TOR  | 2.0                                    | 2.03                                   | 1.5    | 101.5     | 1.119 | 100.02 $\pm$ 1.11             |
|      | 3.0                                    | 2.98                                   | 0.67   | 99.33     |       |                               |
|      | 4.0                                    | 4.01                                   | 0.25   | 100.25    |       |                               |
|      | 5.0                                    | 4.95                                   | 1.0    | 99        |       |                               |

**Table 3: Results of assay of tablets by the proposed methods and statistical evaluation and recovery experiments by standard addition method.**

| Pharmaceuticals/<br>tablets/injection | Drug in<br>tablet<br>( $\mu\text{g mL}^{-1}$ ) | Drug<br>added<br>( $\mu\text{g mL}^{-1}$ ) | Total<br>found<br>( $\mu\text{g mL}^{-1}$ ) | ER<br>% | Recovery<br>% | RSD%  | Reference<br>method<br>mean $\pm$ SD | Proposed<br>method<br>mean $\pm$ SD | Student's<br>t-test | F-test |
|---------------------------------------|--|--|---|---------|---------------|-------|--------------------------------------|-------------------------------------|---------------------|--------|
| GEM (Eg1)                             | 1.5  | 1.0  | 2.48  | 0.8     | 99.2          | 0.399 | 98.28<br>$\pm$ 0.34                  | 99.59<br>$\pm$ 0.397                | 0.267               | 1.363  |
|                                       | 3.0  | 1.0  | 3.98  | 0.5     | 99.5          |       |                                      |                                     |                     |        |
|                                       | 4.5  | 1.5  | 5.97  | 0.5     | 99.5          |       |                                      |                                     |                     |        |
|                                       | 6.0  | 1.0  | 7.01  | 0.14    | 100.14        |       |                                      |                                     |                     |        |
| OND<br>(Ondem)                        | 4.0  | 2  | 5.96  | 0.67    | 99.33         | 0.256 | 100.6<br>$\pm$ 0.85                  | 99.70<br>$\pm$ 0.254                | 1.646               | 0.089  |
|                                       | 6.0  | 2  | 7.98  | 0.25    | 99.75         |       |                                      |                                     |                     |        |
|                                       | 8.0  | 2  | 9.99  | 0.1     | 99.9          |       |                                      |                                     |                     |        |
|                                       | 10   | 2  | 11.98                                       | 0.17    | 99.83         |       |                                      |                                     |                     |        |
| ALF<br>(Alfoo)                        | 3.0  | 1.0  | 3.98  | 0.5     | 99.5          | 0.220 | 100.6<br>$\pm$ 0.6                   | 99.78<br>$\pm$ 0.220                | 1.457               | 0.134  |
|                                       | 6.0  | 1.0  | 6.98  | 0.29    | 99.71         |       |                                      |                                     |                     |        |
|                                       | 9.0  | 1.0  | 9.99  | 0.1     | 99.9          |       |                                      |                                     |                     |        |
|                                       | 12   | 1.0  | 13.0  | 0.0     | 100           |       |                                      |                                     |                     |        |
| DUL<br>(Diligo)                       | 3.0  | 1.0  | 4.01  | 0.25    | 100.25        | 0.219 | 100.20<br>$\pm$ 1.126                | 100.02<br>$\pm$ 0.218               | 1.939               | 0.037  |
|                                       | 5.0  | 1.0  | 5.01  | 16.5    | 100.17        |       |                                      |                                     |                     |        |
|                                       | 7.0  | 1.0  | 7.99  | 0.125   | 99.88         |       |                                      |                                     |                     |        |
|                                       | 9.0  | 1.0  | 9.98  | 0.2     | 99.8          |       |                                      |                                     |                     |        |
| TOR<br>(Dytor)                        | 1.5  | 1.5  | 2.98  | 0.67    | 99.33         | 0.341 | 99.16<br>$\pm$ 0.59                  | 99.75<br>$\pm$ 0.340                | 0.899               | 0.332  |
|                                       | 3.0  | 1.0  | 3.99  | 0.25    | 99.75         |       |                                      |                                     |                     |        |
|                                       | 4.5  | 1.5  | 6.01  | 0.17    | 100.17        |       |                                      |                                     |                     |        |
|                                       | 7.0  | 1.0  | 7.98  | 0.25    | 99.75         |       |                                      |                                     |                     |        |



## CONCLUSION

This method is simple, rapid and offers the advantages of high sensitivity and a wide range of determination without the need for heating or extracting. The other advantages of the present method over the previously described methods include low detection limit with high accuracy and precision. Therefore this method was chosen for the routine analysis of the above drugs in pharmaceuticals and in bulk drug industries.

## ACKNOWLEDGEMENTS

The authors are thankful to the Head, Department of Chemistry, Osmania University, Hyderabad-500007 for providing facilities. One of the authors (KS) is thankful to UGC for JRF.

## REFERENCES

1. Ashok Kumar Bera<sup>1</sup>, Amit Kumar De<sup>2</sup> and Biswajit Pal\*<sup>3</sup>. A Simple, Rapid and Validated Reverse Phase. High Performance Liquid Chromatographic Method for the Estimation of Gemifloxacin in Pharmaceutical Dosage Form. *International Journal of PharmTech Research*, 2014; 6(3):1011-1017.
2. U. L. Narayan<sup>1</sup>, B. Garnaik<sup>2</sup>, S. K. Patro<sup>3</sup> and S. Sahu<sup>4\*</sup>. HPTLC Methods for Determination of Gemifloxacin Mesylate in Rabbit Plasma. *British Journal of Pharmaceutical Research*. 2014; 4 (14): 1707-1714.
3. Narayan, U. L.; Garnaik, B. Patro, S. K.; Sahu, S. HPTLC methods for determination of gemifloxacin mesylate in rabbit plasma. *British Journal of Pharmaceutical Research*, 2014;4(14):
4. Abdallah, Nehad A. HPLC and densitometric TLC methods for simultaneous determination of gemifloxacin with some co-administered drugs in human plasma. *Chromat Separation Techniq.* .2010; 5(2):9.
5. A.R. Rote, S.P. Pingle. Reverse phase-HPLC and HPTLC methods for determination of gemifloxacin mesylate in human plasma. *Journal of Chromatography B*, 2009; 877(29): 3719–3723.
6. Hassan, Syed Saeed Ul; Hayat, Uzma; Tariq, Imran; Ahmad, Irshad; Hayat, Muhammad Munawar; Uzair, Muhammad; Ansari, Muhammad Tayyab. Spectrophotometric method for the determination of Gemifloxacin mesylate in pure and tablet dosage form. *Pak. J. Pharm. Sci*, 2014; 27(5): 1171-1174.

7. Hajera, Khan. Development and validation of a dissolution test with spectrophotometric analysis for gemifloxacin in tablet dosage form. *International Journal of Research in Pharmaceutical and Biomedical Sciences*, 2012; 3(1):
8. Moussa, Bahia Abbas; Mahrouse, Marianne Alphonse; Hassan, Mahmoud Ali; Fawzy, Michael Gamal. Spectrofluorimetric determination of gemifloxacin mesylate and linezolid in pharmaceutical formulations: application of quinone-based fluorophores and enhanced native fluorescence. *Acta Pharm*, 2014; 64(1):15-28.
9. Al-Tamimi, Salma Ali; Alarfaj, Nawal Ahmad; Aly, Fatma Ahmed; Al-Mohaimed, Amal Mohammed, Spectrofluorimetric analysis of gemifloxacin mesylate in pharmaceutical formulations. *Luminescence*, 2014; 29(2): 127–131.
10. Kadi, Adnan A.; Angawi, Rihab F.; Attwa, Mohamed W; Darwish, Hany W; Abdelhameed, Ali Saber. High throughput quantitative bioanalytical LC/MS/MS determination of gemifloxacin in human urine. *Journal of Chemistry*, 2010; 2013 (2013):1155-64.
11. Alarfaj, Nawal Ahmed; Aly, Fatma Ahmed; Al-Tamimi, Salma Ali; El-Tohamy, Maha Farouk. Enhanced silver nanoparticle chemiluminescence method for the determination of gemifloxacin mesylate using sequential injection analysis. *J.Chem.Soc.Pak*, 2013; 35(5):13-19.
12. Asad Raza<sup>1,\*</sup>, Abdul Subhan Ijaz<sup>2</sup>, Atta-ur-Rehman<sup>1</sup> and Uzma Rasheed<sup>2</sup>. Spectrophotometric Determination of Ondansetron Hydrochloride in Pharmaceutical Bulk and Dosage Forms. *Journal of the Chinese Chemical Society*, 2007; 54( 1 ):223–227.
13. R.Kalaichelvi, B.Madhavrao, S.Manikanta, G.Gopinath, M.Usha, D.Venkata ramana. UV spectrophotometric method for determination of Ondansetron Hydrochloride in pure and its formulation. *International Journal of Pharmacy and Pharmaceutical Sciences*, 2012; 4(4).
14. Sradhanjali Patra, AA Choudhury, RK Kar, BB Barik. Spectrophotometric method for ondansetron hydrochloride. *Indian journal of pharmaceutical sciences*, 2007; 69( 6 ) : 840-841.
15. Prashanthi M and Venkateshwarlu G\*. Spectrophotometric estimation of drugs using NBS and amaranth dye couple. *International Journal of Pharmaceutical Research & Analysis*, 2014; 4 (1): 58-64.
16. Kalaichelvi, R.; Rao, B. Madhava; Manikanta, S.; Gopinath, G.; Usha, M.; Ramana, D. Venkata; Rao, D. Srinivasa; Jayachandran, E. UV Spectrophotometric method for

- determination of Ondansetron Hydrochloride in pure and its formulation. *International Journal of Pharmacy & Pharmaceutical Sciences*, 2012; 4:151.
17. Mushabbar basha MD\*, B.Pravena, M.Srinidhi, SK.A.Rahaman. Method Development And Validation Of Ondansetron In Bulk And Pharmaceutical Dosage Form By Stability-Indicating RP-HPLC Method. *International Journal of PharmTech Research*, 2013; 5(1): 86-98.
  18. Bauer S1, Störmer E, Kaiser R, Tremblay PB, Brockmöller J, Roots I. Simultaneous determination of ondansetron and tropisetron in human plasma using HPLC with UV detection. *Biomed Chromatogr*, 2002;16(3):187-90.
  19. Steffen Bauer, Elke Störmer, Rolf Kaiser. Simultaneous determination of ondansetron and tropisetron in human plasma using HPLC with UV detection. *Biomedical Chromatography* 2002; 16(3):187-90.
  20. Singh, Pradeep Kumar; Subas, Chandra Dinda, Development and Validation of a Stability Indicating RP-HPLC Method for Determination of Ondansetron in Orally Disintegrating Films. *International Journal of Research in Pharmacy & Science*, 2013; 3 (1):57.
  21. Roberto F Moreira, Myriam C Salvadori , Cristina P Azevedo, Diogo Oliveira-Silva. Development and validation of a rapid rative bioavailability study. *Biomedical Chromatography*, 2010; 24(11):1220-7.
  22. Lingxia PANG <sup>1#</sup>, Qing WANG <sup>1#</sup>, Youpei WANG <sup>2</sup>, Meiqin ZHENG <sup>2</sup>, Haiya WU <sup>3</sup> & Zhiyi WANG <sup>3\*</sup>, Development and Validation of LC-MS/MS Method for Determination of Ondansetron in rat Plasma and its Application. *Latin American Journal of Pharmacy*, 2012; 31 (2): 305-9.
  23. Radha, G. V. Santosh Naidu, M. <sup>1</sup>. Design of transdermal films of alfuzocin HCl by using a natural polymer tamarind seed polysaccharide extract, *Scholars Research Library Der Pharmacia Lettre*, 2013; 5 (3):457-464.
  24. Safwan Ashour,<sup>1</sup> M. Fawaz Chehna,<sup>2</sup> and Roula Bayram<sup>1</sup> . Spectrophotometric Determination of Alfuzosin HCl in Pharmaceutical Formulations with some Sulphonephthalein Dyes. *Int J Biomed Sci.*, 2006; 2(3): 273–278.
  25. D. Ravikumar <sup>1</sup>, S.V.M. Vardhan<sup>2</sup>, D. Ramachandran<sup>3</sup> and C. Rambabu<sup>4</sup>. Development of new spectrophotometric methods for the determination of Alfuzosin hydrochloride in bulk and pharmaceutical formulations, *Oriental Journal of Chemistry*, 2008; 24(2): 725-728 .
  26. Kanchan Chauhan\*. First and Second Derivative Spectrophotometric Methods for Determination of Alfuzosin in Pharmaceutical Dosage. *American journal of pharmacy and health research*, 2014; 2 ( 7):

27. Mona M. Abdel-Moety<sup>1\*</sup>, Nagiba Y.M. Hassan<sup>2</sup>, Samar G. Abdel-Hamid<sup>1</sup>, Abdel-Aziz A. Abdel-Aleem<sup>2</sup>. Spectrophotometric and Potentiometric Methods for the Determination of Alfuzosin Hydrochloride and Doxazosin Mesylate in Drug Substances and Drug products. *International Journal of ChemTech Research*, 2014; 6(5): 2875-2886.
28. K. Damodar Reddy, B. Vijay Kumar, K. Sayanna & G.Venkateshwalu\*. Spectrophotometric determination of drugs based on oxidation by acidic KMnO<sub>4</sub>. *World journal of pharmacy and pharmaceutical sciences*, 2014; 3(8): 812-824.
29. Ashok K. Shakya<sup>1</sup>, Tawfiq A. Arafat<sup>2</sup>, Ahmad Abuawaad<sup>2</sup>, Hamza Al-Hroub<sup>2</sup>, Munther Melhim<sup>2</sup>. Simple and Rapid HPLC Method for the Determination of Alfuzosin in Human Plasma. *Jordan Journal of Pharmaceutical Sciences*, 2010;3(1):
30. Salah Fayed A<sup>1</sup>, Abdel-Aaty Shehata M, Yehia Hassan N, El-Weshahy S.A Validated HPLC and HPTLC stability-indicating methods for determination of alfuzosin hydrochloride in bulk powder and pharmaceutical formulations. *J Sep Sci.*, 2006; 29(18):2716-24.
31. Noel Alex Gomes. Ashutosh Pudage , Santosh S. Joshi. Rapid and Sensitive LC–MS–MS Method for the Simultaneous Estimation of Alfuzosin and Dutasteride in Human Plasma. *Chromatographia*, 2008; 69(1):9-18.
32. Safwan Ashour\*and Mouhammed Khateeb, Conductometric Titration Method for Determination of Alfuzosin Hydrochloride and Fexofenadine Hydrochloride Using Sodium Tetraphenylborate. *Canadian Chemical Transactions*, 2013; 1 (4): 292-304.
33. B. Mohammed Ishaq\*<sup>1</sup>, Dr. K. Vanitha Prakash<sup>1</sup>, C. Hari Kumar<sup>2</sup>, G. Usha Rani<sup>3</sup>, P. Ramakrishna<sup>4</sup> . Colorimetric Determination of Alfuzosin HCl in Pharmaceutical Formulations. *Journal of Pharmacy Research*, 2011; 4(1):226-228.
34. Shahnawaz, Sheikh; Siddiqui, Abdul Wadood; Masroor, Mir Tariq; Arora, Vandana. Stability-indicating HPTLC method for determination of duloxetine hydrochloride in bulk drug and tablet formulation .*Chromatography Research International*, 2011; 404189, 5 pages.
35. Lakshmana Prabu, S.; Srinivasan, M.; Thiyagarajan, S.; Marina, Queeni .Determination of duloxetine hydrochloride in pharmaceutical formulation by HPLC with UV detection. *International Journal of ChemTech Research*, 2010;.2(3): 1441-1444.
36. Sejal K Patel, NJ Patel, KM Patel, PU Patel, BH Patel. Estimation of duloxetine hydrochloride in pharmaceutical formulations by RP-HPLC method. *Indian J Pharm Sci*, 2008 ; 70(6): 825-827.

37. Chusena Narasimharaju Bhimanadhuni, Devala Rao Garikapati, Chintha Srinivas, Bhimanadhuni *et al.* Development and validation of RP-HPLC method for determination of Duloxetine hydrochloride in bulk and dosage form. *International Current Pharmaceutical Journal*, 2012; 1(5):98-102.
38. Navneet Kumar,<sup>1</sup>, D. Sangeetha,<sup>2</sup> and P. Balakrishna<sup>1</sup>. Development and validation of a UPLC method for the determination of duloxetine hydrochloride residues on pharmaceutical manufacturing equipment surfaces. *Pharm Methods*, 2011; 2(3): 161–166.
39. Reddy, T. Srinivasa; Prasad, U. Viplava; Acharyulu, M. L. N.; Srinivas, B. V.; Sastry, C. S. P. Visible spectrophotometric methods for the determination of duloxetine hydrochloride in bulk and dosage forms. *Scholars Research Library ,Der Pharma Chemica*, 2012; 4(6):2427-2433.
40. R. Vijay Amritha Raj, T. Ramesh<sup>1</sup> and A. Phani kumar<sup>1</sup>. A Validated UV spectrophotometric determination of an antidepressant drug – Duloxetine Hydrochloride from capsule formulations. *International Journal of Pharma and Bio Sciences*, 2011;2(1).
41. Thulasamma, P.; Venkateswarlu, P. Development and validation of RP-HPLC method for the quantitative estimation of toremide in pharmaceutical dosage forms and human serum. *International Journal of ChemTech Research*, 2014; 6(2) :1103-1109.
42. Deshpande, P. B.; Gandhi, S. V.; Gaikwad, N. V.; Khandagle, K. S. A simple and sensitive RP-HPLC method for simultaneous estimation of toremide and spironolactone in combined tablet dosage form. *Journal Acta Chromatographica*, 2012; 24( 1):15-22.
43. Gaikwad, Nilesh V.; Deshpande, Padmanabh B.; Gandhi, Santosh V.; Khandagale, Kapil, High Performance Thin Layer Chromatographic determination of spironolactone and toremide in combined tablet dosage form. *K. Research Journal of Pharmacy and Technology*, 2010, 3(4), 1106- 1108.
44. Kakde, R.; Chaudhary, N.; Barsagade, A.; Kale, D. Stability-indicating HPTLC method for analysis of toremide in pharmaceutical preparations. *Acta Chromatographica*, 2011;23(1):145-155.
45. Rajesh Shukla, Nidhi Bhavsar, Vikas Pandey, Dilip Golhani, Alok Pal Jain. RP-HPLC Determination of Toremide in Pharmaceutical Formulation by Liquid. *Asian Journal of Biomedical and Pharmaceutical Sciences*, 2012; 2(15).
46. Rujuta D. Patel\*, Dr. Dilip G. Maheshwari, RP-HPLC Method for the estimation of Toremide and Amiloride hydrochloride in their combined dosage form. *IAJPR.*, 2014; 4(4): 2079-2086.

47. Hiresh K. Golher\*<sup>1</sup>, Kavita Kapse<sup>1</sup> and Sachin K. Singh<sup>2</sup>. Simultaneous Spectrophotometric Estimation of Torsemide and Spironolactone in Tablet Dosage Form. International Journal of PharmTech Research, 2010; 2(4):2246-2250.
48. R. Laxman, Acharya Ashish, Jain Vinay, Bhardwaj Sudhir and Jain Deepti. Development and validation of RP-HPLC and UV spectrophotometric methods simultaneous determination of spironolactone and torsemide in pharmaceutical dosage form. IJRAP 2010; 1 (2):459-467
49. Patel Grishma B.\*, Hemant Patel. Simultaneous determination of Amiloride hydrochloride and Torsemide in combined dosage form using spectrophotometric methods. World journal of pharmacy and pharmaceutical sciences, 2014; 3(4): 1351-1360.
50. Nilesh Jain\*<sup>1</sup>, Ruchi Jain, Navneet Thakur, Brahm Prakash Gupta, Jitendra Banweer and Surendra Jain, 9. Novel Spectrophotometric Quantitative Estimation of Torsemide in Tablets Using Mixed Hydrotropic Agent, Scholars Research Library, 2010; 2(3): 249-254.
51. Patel, Rujuta D.; Maheshwari, Dilip G. 1. Dual wavelength spectrophotometric method for simultaneous estimation of torsemide and amiloride hydrochloride in their combined dosage form, Scholars Research Library, 2014; 6 (2):43-49.
52. Marothu Vamsi Krishna and Dannana Gowri Sankar, Simple Spectrophotometric Determination of Torsemide in Bulk Drug and in Formulations, Journal of Chemistry, 2008; 5 (3): 473-478.